Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded a decrease of -26.54%. However, over the last six months, the performance has been stronger by -33.50%. The price of CRVS decreased -3.91% over the last 30 days. And in the last five days, it has fallen by -16.20%.
Corvus Pharmaceuticals Inc experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $10.00 on 11/13/24, while the lowest price for the same period was registered at $1.30 on 04/18/24.
52-week price history of CRVS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Corvus Pharmaceuticals Inc’s current trading price is -60.70% away from its 52-week high, while its distance from the 52-week low is 202.31%. The stock’s price range during this period has varied between$1.30 and $10.00. The Corvus Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.04 million for the day, a figure considerably higher than their average daily volume of 0.58 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Corvus Pharmaceuticals Inc (CRVS) has experienced a quarterly decline of -22.79% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 252.53M and boasts a workforce of 28 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 6.13, with a change in price of -4.71. Similarly, Corvus Pharmaceuticals Inc recorded 875,718 in trading volume during the last 100 days, posting a change of -54.51%.
CRVS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CRVS stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.00.
CRVS Stock Stochastic Average
As of today, Corvus Pharmaceuticals Inc’s raw stochastic average for the last 50 days stands at 7.53%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 13.86%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 36.27% and 44.08%, respectively.
